Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

729
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
729
Drug Discovery: Overview01:26

Drug Discovery: Overview

7.9K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
7.9K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

6.3K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.3K
Drug-Receptor Bonds01:25

Drug-Receptor Bonds

2.9K
Drug-receptor bonds are formed through various chemical forces when drugs interact with target cells. Covalent bonds, strong and irreversible, are exemplified by DNA-alkylating anticancer agents that inhibit cell division. However, such irreversible drug binding lacks selectivity and can modify the DNA of the surrounding healthy cells. Covalent binding often contributes to tissue toxicity, as seen with chloroform and paracetamol metabolites binding to the liver, causing hepatotoxicity.
In...
2.9K
Principles of Drug Action01:24

Principles of Drug Action

6.0K
Drugs are chemical substances that modify biological responses by interacting with macromolecular targets such as receptors, ion channels, transporters, and enzymes. Pharmacodynamics describes the course of action of drugs leading to the physiological effect at a specific site in the body.
Drugs can be agonists or antagonists. Like the endogenous ligands, agonists always bind and activate the target to produce a cellular response. Agonist binding induces a conformational change which in turn...
6.0K
Ligand Binding Sites02:40

Ligand Binding Sites

7.7K
7.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

SARM1 base-exchange inhibitors induce SARM1 activation and neurodegeneration at low doses.

npj drug discovery·2026
Same author

Altered flow of information in attention-deficit/hyperactivity disorder.

Translational psychiatry·2026
Same author

Streamlined calculation of kidney function using dynamic contrast-enhanced MRI with population-based arterial input function and a whole-kidney model.

European radiology experimental·2026
Same author

Altered flow of information in temporal lobe epilepsy.

Neurobiology of disease·2026
Same author

Automated Coregistered Segmentation for Volumetric Analysis of Multiparametric Renal MRI.

Magnetic resonance in medicine·2026
Same author

Multiparametric MRI for Predicting Renal Function Deterioration and Chronic Kidney Disease Development in Patients Undergoing Nephrectomy for Renal Masses: A Pilot Study.

Journal of magnetic resonance imaging : JMRI·2026
Same journal

How Much Chirality is Enough?

Chimia·2026
Same journal

Raman Optical Activity (ROA) as an Emerging Standard in Molecular Chirality Measurements - A Perspective.

Chimia·2026
Same journal

Molecular Chirality: From Structure to the Quantum Dynamics of Tunnelling, Parity Violation, a Molecular Quantum Switch and the Possible Astrophysical Detection of Homochirality as a Signature of Extraterrestrial Life.

Chimia·2026
Same journal

Shining Light on Chiral Monolayer-protected Metal Clusters.

Chimia·2026
Same journal

Spin Depolarization Mechanisms in Halide Perovskite Semiconductors.

Chimia·2026
Same journal

New Insights into Circularly Polarized Luminescence from Chromium(III) Spin-Flip Emitters.

Chimia·2026
See all related articles

Related Experiment Video

Updated: Jul 9, 2025

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
08:31

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

5.0K

Details Matter in Structure-based Drug Design.

Bernd Kuhn1, Jens-Uwe Peters2, Markus G Rudolph3

  • 1Roche Pharma Research and Early Development, Innovation Center Basel, F. Hoffmann-La Roche Ltd., CH-4070 Basel, Switzerland. bernd.kuhn@roche.com.

Chimia
|December 4, 2023
PubMed
Summary
This summary is machine-generated.

Small chemical changes significantly impact drug design by altering ligand conformation and protein interactions. Data mining structural databases reveals subtle effects crucial for optimizing drug candidates.

Keywords:
Intramolecular hydrogen bondLigand strainMolecular interactionsPDE10

More Related Videos

Nano-Differential Scanning Fluorimetry for Screening in Fragment-based Lead Discovery
06:26

Nano-Differential Scanning Fluorimetry for Screening in Fragment-based Lead Discovery

Published on: May 16, 2021

4.8K
Incorporating Target Protein Structure Flexibility and Dynamics in Computational Drug Discovery Using Ensemble-Based Docking Analysis
08:49

Incorporating Target Protein Structure Flexibility and Dynamics in Computational Drug Discovery Using Ensemble-Based Docking Analysis

Published on: June 20, 2025

196

Related Experiment Videos

Last Updated: Jul 9, 2025

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
08:31

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

5.0K
Nano-Differential Scanning Fluorimetry for Screening in Fragment-based Lead Discovery
06:26

Nano-Differential Scanning Fluorimetry for Screening in Fragment-based Lead Discovery

Published on: May 16, 2021

4.8K
Incorporating Target Protein Structure Flexibility and Dynamics in Computational Drug Discovery Using Ensemble-Based Docking Analysis
08:49

Incorporating Target Protein Structure Flexibility and Dynamics in Computational Drug Discovery Using Ensemble-Based Docking Analysis

Published on: June 20, 2025

196

Area of Science:

  • Medicinal Chemistry
  • Structural Biology
  • Computational Chemistry

Background:

  • Structure-based drug design (SBDD) necessitates optimizing target protein interactions and minimizing ligand strain.
  • Subtle chemical modifications can drastically alter a ligand's preferred conformation and binding preferences.

Purpose of the Study:

  • To highlight the critical importance of minor structural details in SBDD.
  • To demonstrate the utility of data mining in crystal structure databases for understanding molecular recognition and guiding drug design.

Main Methods:

  • Analysis of a Roche project targeting phosphodiesterase 10.
  • Data mining of the Cambridge Structural Database (CSD) to identify preferred intramolecular hydrogen bonding motifs.
  • Utilizing the Protein Data Bank (PDB) to derive propensities for protein-ligand interactions.

Main Results:

  • Small structural variations can lead to significant changes in ligand behavior.
  • CSD analysis identified key structural motifs for intramolecular hydrogen bonding.
  • PDB analysis provided insights into protein-ligand interaction preferences.

Conclusions:

  • Attention to subtle structural details is paramount for successful SBDD.
  • Crystal structure databases are invaluable resources for both understanding molecular recognition and developing molecular design tools.